Recombinant Ephb4-Hsa Fusion Protein
Gallbladder Carcinoma
Explore 30 assets in Gallbladder Carcinoma →Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
University of Southern California
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
27Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02495896CT.gov Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gallbladder Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Ephb4-Hsa Fusion Protein (this asset) | University of Southern California | P1 | CC · 42 |
| Fluorouracilum | Lisata Therapeutics, Inc. | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Lisata Therapeutics, Inc. | P2 | B |
| Pembrolizumab | Seagen, a wholly owned subsidiary of Pfizer | P2 | B |
| Durvalumab | Lisata Therapeutics, Inc. | P2 | B |
| Capecitabine | Seagen, a wholly owned subsidiary of Pfizer | P2 | B |
| Oxaliplatin | Lisata Therapeutics, Inc. | P2 | B |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer | M.D. Anderson Cancer Center | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
+28 more in the Gallbladder Carcinoma cohort
Other indications for Recombinant Ephb4-Hsa Fusion Protein
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infiltrating Bladder Urothelial Carcinoma | — | P2/3 | CCC · 55 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 55 |
| Urothelial Carcinoma | — | P2/3 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant Ephb4-Hsa Fusion Protein in Gallbladder Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-ephb4-hsa-fusion-protein-gallbladder-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →